Chiesi Group Unveils New Biotechnology Hub in Italy with a €400 Million Investment Commitment
The Chiesi Group, a global biopharmaceutical research entity, has officially opened its Biotech Center of Excellence in Parma, Italy. This advanced facility is focused on the development and manufacture of monoclonal antibodies, enzymes, and various proteins.
This center aims to combine research with production under one roof, thereby speeding up the development process and allowing for a smoother transition from drug development to manufacturing.
“The COVID-19 pandemic has highlighted the urgent necessity for swift and effective solutions to global health issues,” stated Giuseppe Accogli, CEO of Chiesi. “We understand that the future of healthcare rests on our capacity to innovate and adapt rapidly. Our newly established Biotech Center of Excellence will empower us to secure an independent production capacity, safeguarding the well-being of our patients while ensuring timely delivery of new therapies.”
“By merging research and manufacturing processes, we can enhance the speed at which we move from clinical trials to commercial production, ultimately improving patient access to essential treatments. Our objective is to cultivate a more sustainable and adaptive healthcare system that can effectively tackle future global health crises.”
The Biotech Center of Excellence will facilitate the manufacturing of both small and large quantities of drugs, whether they are experimental or already approved, thus ensuring a seamless progression from clinical studies to commercial output. This facility will specifically bolster Chiesi’s primary focus areas: respiratory issues, specialized care, and rare diseases.
Chiesi plans to invest approximately €400 million in this new center. This investment includes €120 million earmarked for infrastructure and an additional €260 million allocated over the next six years for materials, cutting-edge technologies, talent development, and training. By 2025, the center is anticipated to create around 200 specialist roles along with 80 positions in technical fields.
This financial commitment reflects Chiesi’s aim to foster a more robust and sustainable healthcare system in Europe, addressing the pressing needs for skills development, research and development, overcoming regulatory challenges, and minimizing reliance on raw materials.
“At Chiesi, we are convinced that innovation is crucial to advancement in healthcare. By dedicating over 20% of our revenue to R&D, we are investing not only in the future of medicine but also in enhancing the lives of patients while tackling global healthcare challenges,” Accogli remarked.
“Our new Biotech Center epitomizes this commitment by providing an advanced facility for the development of pioneering therapies to market more swiftly. This investment highlights our resolve to lead in medical innovation and address significant unmet medical needs, particularly in rare disease treatment.”